Across TCGA pan-cancer cohorts, CCDC162P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CCDC162P data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CCDC162P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC162P expression acts as an unfavorable survival marker.
UCEC are the cancer types where CCDC162P Mutation most reproducibly stratifies survival.